Skip to content
drillr.ai
Sign up

02105.HK

Laekna, Inc.

HKSE · Healthcare · Biotechnology · CN

HKD 5.61
−0.44%
Ask drillr

  • Oct 21, 2026, 01:44 UTC

    Laekna, Inc. shares rose as much as 14.58% to HK$19.33 in morning trading.

    Source:

  • Oct 21, 2026, 01:44 UTC

    Laekna, Inc. announced that it may repurchase its H shares on the Hong Kong Stock Exchange for up to HK$100 million, including transaction costs.

    Source:

  • Oct 20, 2026, 01:54 UTC

    Laekna, Inc.’s share-price volatility triggered a trading cooling-off period at 09:45, with a price limit of HK$21.46 and a lower limit of HK$14.32.

    Source:

  • Oct 20, 2026, 01:54 UTC

    Laekna, Inc. entered a cooling-off period after its share-price volatility triggered the market volatility control mechanism, with a price limit of HK$25.74 and a lower limit of HK$17.17.

    Source:

  • Oct 13, 2026, 01:04 UTC

    Laekna, Inc. said it is actively seeking a global-capable partner to accelerate development and commercialization of its LAE102 weight-control drug candidate.

    Source:

  • Oct 13, 2026, 00:29 UTC

    Laekna, Inc. completed enrollment of subjects in the high-dose group to further assess LAE102's efficacy and safety over a 24-week treatment period.

    Source:

  • Oct 13, 2026, 00:29 UTC

    Laekna, Inc. reported that the 24-week LAE102 treatment was well tolerated, with no serious adverse events or reports of diarrhea, muscle cramps, or acne.

    Source:

  • Oct 13, 2026, 00:29 UTC

    Laekna, Inc. announced completion of treatment for the low-dose group in its 24-week LAE102 monotherapy study, reporting encouraging weight loss alongside observed muscle gain and fat reduction.

    Source:

  • Sep 30, 2026, 03:44 UTC

    Chinese innovative drug stocks rallied in both Hong Kong and mainland China on Wednesday, with CanSino Biologics up 19% and Laekna up 18.6% in Hong Kong, and Sinovent up 14% and CSPC Innovation up 8.5% on the A-share market.

    Source:

  • Sep 1, 2026, 00:22 UTC

    Laekna Healthcare initiated a Phase I clinical study of LAE118 for advanced solid tumors in China and enrolled the first subject.

    Source:

  • Aug 25, 2026, 17:43 UTC

    Laekna Inc. reported interim results for the six months ended June 2026, with revenue of RMB 150 million and a net loss narrowed to RMB 2.55 million from RMB 130 million a year earlier, with no dividend declared.

    Source:

  • Aug 17, 2026, 01:27 UTC

    Laekna (02105.HK) issued a profit alert, expecting revenue of RMB 145-155 million for the six months ending June 30, 2026, compared to zero in the prior year period, and a net loss of no more than RMB 5 million, a 96% reduction from RMB 130 million a year earlier.

    Source:

  • Aug 12, 2026, 00:44 UTC

    Laekna announced that its new drug application for LAE002 (afuresertib) has been accepted by China's National Medical Products Administration for review, for treating HR+/HER2- locally advanced or metastatic breast cancer patients with PIK3CA/AKT1/PTEN alterations.

    Source: